Caring for cancer patients is my passion and inspiration as a physician. I strive to make clinical trials available to all patients because clinical trials are the only path to finding a cure, and because - where there is life there is hope.
Work and Credentials:
Primary Location
Position
Medical Oncologist, Virginia Cancer Specialists Research Institute
Board Certification
Medical Oncology, Hematology and Internal Medicine
Fellowship
Advanced Developmental Therapeutics, National Cancer Institute, National Institutes of Health Hematology and Oncology, University of Cincinnati
Residency
Saint Louis University School of Medicine
Medical School
University of Damascus School of Medicine, Damascus, Syria
Special Interests
Clinical Trials
Mohamad Adham Salkeni, MD, FRCPC earned his medical degree from the University of Damascus. He then completed his residency in internal medicine at St. Louis University and fellowship in hematology and oncology at the University of Cincinnati. During his medical training, he was engaged in bench and translational research investigating inflammatory modulation of the blood-brain barrier in vivo, published in the Journal of Neuroimmune Pharmacology; and established a tumor-informed assay for detecting circulating mutant DNA of brain cancer, published in the Journal of Neuro-Oncology. Following training completion, he joined West Virginia University as an Assistant Professor and was later promoted to Associate Professor, where he also served as Medical Director for the Clinical Trials Research Unit and Co-Chair of the Breast Cancer Leadership Committee. Interested in early drug development, Dr. Salkeni elected to move on to the National Cancer Institute, National Institutes of Health (NCI/NIH) in Bethesda, Maryland, where he completed a fellowship in Advanced Developmental Therapeutics. During his time spent at the NCI, he participated in concept development and design of early phase clinical trials of novel immunotherapeutics and small molecules, and authored a book chapter on resistance mechanisms to immunotherapy.
Dr. Salkeni is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), American Society of Hematology (ASH), and the Society for Immunotherapy of Cancer (SITC). Dr. Salkeni joined Virginia Cancer Specialists as a Clinical Investigator in Phase 1 cancer clinical trials, in collaboration with NEXT Oncology.
In his spare time, he enjoys swimming and spending time outdoors with family.
Physician Publications
June 15, 2022
Abstract CT115: Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+)
Read MoreJune 1, 2022
A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.
Read MoreMore Publications by M. Adham Salkeni, MD, FRCPC
January 1, 2022
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Read MoreDecember 1, 2021
Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer
Read MoreDecember 1, 2021
Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer
Read MoreOctober 12, 2021
Guest Editor and Reviewer Acknowledgments: 2021
Read MoreSeptember 24, 2021
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Read MoreJune 15, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Read MoreJanuary 1, 2021
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Read MoreJanuary 1, 2021
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Read MoreNovember 3, 2020
Guest Editor and Reviewer Acknowledgments: 2020
Read MoreOctober 10, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
Read MoreSeptember 20, 2019
Understanding palbociclib practice patterns in a real-world setting.
Read MoreApril 1, 2019
NEDD9 adaptor protein regulates HER2-driven metastasis in breast cancer
Read MoreMarch 8, 2019
The Stem Cell Phenotype of Aggressive Breast Cancer Cells
Read MoreFebruary 15, 2019
Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus
Read MoreFebruary 1, 2019
Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease
Read MoreJanuary 1, 2019
Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting
Read MoreDecember 1, 2018
Switching endocrine therapy in breast cancer as a strategy for musculoskeletal symptoms, tolerance, and adherence.
Read MoreOctober 10, 2018
First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study
Read MoreOctober 1, 2018
Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy
Read MoreMay 20, 2018
NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).
Read MoreOctober 1, 2017
Metastatic breast cancer: Endocrine therapy landscape reshaped
Read MoreJune 1, 2017
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Read MoreMay 20, 2017
Prognostic factors in breast cancer patients evaluated by PET/CT prior to neoadjuvant chemotherapy.
Read MoreMay 20, 2017
Retrospective analysis of the role of CA 15-3 as a biomarker for breast cancer relapse.
Read MoreMarch 29, 2017
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Read MoreMarch 1, 2017
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
Read MoreOctober 10, 2016
Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER + /HER2- metastatic breast cancer (MBC)
Read MoreAugust 15, 2016
Abstract B20: Development of metastatic patient-derived xenografts (PDXs) for accurate assessment of anti-metastatic therapeutics in pre-clinical settings
Read MoreAugust 1, 2016
Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
Read MoreMay 20, 2016
Longitudinal study of arm impairments, function and quality of life following mastectomy.
Read MoreApril 1, 2016
Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses
Read MoreMarch 16, 2016
Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses
Read MoreAugust 11, 2015
Resolution of Telangiectasia Macularis Eruptiva Perstans with successful treatment of synchronous large granular lymphocytic leukemia
Read MoreMay 1, 2015
Optimal management of sentinel lymph node positive biopsy patients in early breast cancer
Read MoreMarch 19, 2015
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
Read MoreMarch 1, 2015
P1.14 - A Dose Escalation Single Arm Phase Ib Combination Study of BEZ235 with Everolimus in Patients with Advanced Solid Malignancies
Read MoreFebruary 15, 2015
Abstract PD3-04: Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10
Read MoreNovember 15, 2014
MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1
Read MoreOctober 16, 2014
MicroRNAs 206 and 21 Cooperate To Promote RAS–Extracellular Signal-Regulated Kinase Signaling by Suppressing the Translation of RASA1 and SPRED1
Read MoreOctober 1, 2013
Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients
Read MoreJuly 23, 2013
Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients
Read MoreMay 20, 2013
Patient selection for anti-EGFViii therapies in glioblastoma multiforme (GBM): Use of circulating tumor DNA.
Read MoreMay 20, 2013
BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study.
Read MoreApril 11, 2013
Bevacizumab and Glioblastoma Multiforme: A Thrombosis and Bleeding Dilemma (A Case Report and a Brief Review of the Literature).
Read MoreMarch 1, 2013
Patient Selection for Anti-Egfviii Therapies in Glioblastoma Multiforme (GBM): Use of Circulating Tumor DNA
Read MoreMay 20, 2012
Identification of a new mutation in the EGFR ligand-binding domain: Predictive factor for cetuximab antitumor activity in head and neck carcinoma?
Read MoreMay 5, 2012
A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme.
Read MoreJune 1, 2009
Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways
Read MoreNovember 28, 2008
Lipopolysaccharide Impairs Blood–Brain Barrier P-glycoprotein Function in Mice Through Prostaglandin- and Nitric Oxide-Independent Pathways
Read More